Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Healthtrust
Argus Health
Citi
QuintilesIMS
Cerilliant
Chubb
Daiichi Sankyo
Chinese Patent Office

Generated: December 11, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,247,416

« Back to Dashboard

Which drugs does patent 8,247,416 protect, and when does it expire?

Patent 8,247,416 protects LYNPARZA and is included in one NDA.

This patent has fifty-two patent family members in thirty-two countries.

Summary for Patent: 8,247,416
Title:Phthalazinone derivative
Abstract: 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-p- hthalazin-1-one as crystalline Form A.
Inventor(s): Menear; Keith Allan (Cambridge, GB), Ottridge; Anthony Peter (Cambridge, GB), Londesbrough; Derek John (Sunderland, GB), Hallett; Michael Raymond (Sunderland, GB), Mulholland; Keith Raymond (Macclesfield, GB), Pittam; John David (Macclesfield, GB), Laffan; David Dermot Patrick (Macclesfield, GB), Ashworth; Ian Woodward (Macclesfield, GB), Jones; Martin Francis (Macclesfield, GB), Cherryman; Janette Helen (Macclesfield, GB)
Assignee: Kudos Pharmaceuticals Limited (London, GB)
Application Number:12/500,900
Patent Claim Types:
see list of patent claims
Compound; Use;

Drugs Protected by US Patent 8,247,416

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca Pharms LYNPARZA olaparib CAPSULE;ORAL 206162-001 Dec 19, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 8,247,416

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 063320 ➤ Try a Free Trial
Austria 528296 ➤ Try a Free Trial
Australia 2007311766 ➤ Try a Free Trial
Brazil PI0717125 ➤ Try a Free Trial
Canada 2664275 ➤ Try a Free Trial
Canada 2875147 ➤ Try a Free Trial
Chile 2007002967 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
McKesson
Fuji
Federal Trade Commission
Deloitte
Cantor Fitzgerald
US Army
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.